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Background
Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-
catabolizing enzyme that is expressed in many cancers
and induces immune tolerance by suppressing T cell
responses. Epacadostat is a potent, selective oral inhibi-
tor of IDO1. A dose-escalation study of epacadostat
with ipilimumab in patients with advanced melanoma
showed favorable ORR, disease control rate (DCR), and
PFS in immunotherapy-naïve patients [1]. Preliminary
data of epacadostat with pembrolizumab in patients
with selected advanced cancers are reported.
Methods
This is an ongoing dose-escalation and dose-expansion
study of epacadostat with pembrolizumab in patients
with Stage IIIB, IV, or recurrent NSCLC, melanoma,
transitional cell carcinoma (TCC), RCC, endometrial
adenocarcinoma (EA), or SCCHN with a 3+3+3 Phase I
design (NCT02178722). Patients previously treated with
anti-PD-1 or anti-CTLA-4 therapies were excluded.
Enrollment is complete in the epacadostat 25 mg BID,
50 mg BID, and 100 mg BID cohorts with pembrolizu-
mab 2 mg/kg IV q3 weeks. Expansion cohorts of epaca-
dostat 50 mg BID, 100 mg BID, and 300 mg BID with
pembrolizumab 200 mg are enrolling. Safety, tolerability,
and investigator-assessed tumor response (RECIST 1.1)
were evaluated.
Results
As of August 21, 2015, 54 patients were enrolled. This
report includes safety data on 28 patients (melanoma
[n=11], RCC [n=5], NSCLC [n=5], TCC [n=3], EA and
SCCHN [n=2 each]) and 19 patients evaluable for effi-
cacy as of July 13, 2015. A DLT (grade 3 rash) was
observed in 1/8 patients with epacadostat 50 mg BID/
pembrolizumab 2 mg/kg; no DLTs were observed with
epacadostat 100 mg/pembrolizumab 2 mg/kg. The most
common (≥20%) all grade AEs were fatigue, diarrhea,
rash, arthralgia, and nausea; the majority of these were
grade 1 or 2. Grade ≥3 immune-related AEs were muco-
sal inflammation and rash (n=1 [4%] each). Reductions
in tumor burden were observed in 15/19 evaluable
patients. Responses were observed in all tumor types
(Table 1), and all are ongoing. In 7 evaluable melanoma
patients, ORR was 57% and DCR was 86%, which
included 2 CRs. In 5 evaluable RCC patients, ORR was
40% and DCR was 80%. Based on a PK-PD model for
epacadostat, nearly all patients’ Cavg exceeded the IC50,
the range of active drug exposure seen in preclinical
models.
Conclusions
Epacadostat with pembrolizumab was generally well toler-
ated and efficacy data suggest promising clinical activity.
Correlations between biomarker expression and response
are being evaluated. Enrollment in expansion cohorts is
ongoing. Updated data will be presented.
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Table 1
Evaluable patients* Melanoma RCC TCC NSCLC EA SCCHN
n(%) (n=7) (n=5) (n=2) (n=2) (n=2) (n=1)
ORR (CR+PR) 4 (57) 2 (40) 1 (50) 1 (50) 1 (50) 1 (100)
CR 2 (29) 0 0 0 0 0
PR 2 (29) 2 (40) 1 (50) 1 (50) 1 (50) 1 (100)
SD 2 (29) 2 (40) 0 1 (50) 0 0
DCR (CR+PR+SD) 6 (86) 4 (80) 1 (50) 2 (100) 1 (50) 1 (100)
PD 1 (14) 0 1 (50) 0 0 0
Not assessable 0 1 (20) 0 0 1 (50) 0
*Patients with ≥ 1 post-baseline response assessment or discontinued from study or died before response could be assessed.
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